These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 20357743)

  • 1. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
    Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
    Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease.
    Thatipelli MR; Pellikka PA; McBane RD; Rooke TW; Rosales GA; Hodge D; Herges RM; Wysokinski WE
    J Vasc Surg; 2007 Jul; 46(1):62-70; discussion 70. PubMed ID: 17583463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction rule for cardiovascular events and mortality in peripheral arterial disease patients: data from the prospective Second Manifestations of ARTerial disease (SMART) cohort study.
    Sprengers RW; Janssen KJ; Moll FL; Verhaar MC; van der Graaf Y;
    J Vasc Surg; 2009 Dec; 50(6):1369-76. PubMed ID: 19837547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
    J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.
    Winkel TA; Hoeks SE; Schouten O; Zeymer U; Limbourg T; Baumgartner I; Bhatt DL; Steg PG; Goto S; Röther J; Cacoub PP; Verhagen HJ; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2010 Jul; 40(1):9-16. PubMed ID: 20385507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
    Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation.
    Bianchi C; Montalvo V; Ou HW; Bishop V; Abou-Zamzam AM
    Ann Vasc Surg; 2007 Mar; 21(2):163-6. PubMed ID: 17349357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication underuse during long-term follow-up in patients with peripheral arterial disease.
    Hoeks SE; Scholte op Reimer WJ; van Gestel YR; Schouten O; Lenzen MJ; Flu WJ; van Kuijk JP; Latour C; Bax JJ; van Urk H; Poldermans D
    Circ Cardiovasc Qual Outcomes; 2009 Jul; 2(4):338-43. PubMed ID: 20031859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of ischemic events in patients with peripheral arterial disease design, baseline characteristics and 2-year results an observational study.
    Blinc A; Kozak M; Sabovic M; Božic M; Stegnar M; Poredoš P; Kravos A; Barbic-Žagar B; Pohar Perme M; Stare J;
    Int Angiol; 2011 Dec; 30(6):555-66. PubMed ID: 22233617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of declining ankle-brachial index values in patients with suspected or known peripheral arterial disease.
    Feringa HH; Karagiannis SE; Schouten O; Vidakovic R; van Waning VH; Boersma E; Welten G; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2007 Aug; 34(2):206-13. PubMed ID: 17481930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of unrecognized peripheral arterial disease (PAD) using ankle-brachial index in high cardiovascular risk patients free from symptomatic PAD.
    Mourad JJ; Cacoub P; Collet JP; Becker F; Pinel JF; Huet D; Sevestre-Pietri MA; Priollet P;
    J Vasc Surg; 2009 Sep; 50(3):572-80. PubMed ID: 19560312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction.
    Espinola-Klein C; Rupprecht HJ; Bickel C; Lackner K; Savvidis S; Messow CM; Munzel T; Blankenberg S;
    Circulation; 2008 Aug; 118(9):961-7. PubMed ID: 18697822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
    Ohtake T; Sato M; Nakazawa R; Kondoh M; Miyaji T; Moriya H; Hidaka S; Kobayashi S
    Ther Apher Dial; 2014 Feb; 18(1):1-8. PubMed ID: 24499078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of peripheral arterial occlusive disease with major coronary events in a mediterranean population with low coronary heart disease incidence.
    Merino J; Planas A; De Moner A; Gasol A; Contreras C; Marrugat J; Vidal-Barraquer F; Clarà A
    Eur J Vasc Endovasc Surg; 2008 Jul; 36(1):71-6. PubMed ID: 18396072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors.
    Feringa HH; Karagiannis SE; Chonchol M; Vidakovic R; Noordzij PG; Elhendy A; van Domburg RT; Welten G; Schouten O; Bax JJ; Berl T; Poldermans D
    J Am Soc Nephrol; 2007 Jun; 18(6):1872-9. PubMed ID: 17475817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet and antithrombotic treatment of patients with peripheral arterial disease.
    Poredos P; Jezovnik MK
    Int Angiol; 2010 Feb; 29(1):20-6. PubMed ID: 20224527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
    Stone WM; Demaerschalk BM; Fowl RJ; Money SR
    J Stroke Cerebrovasc Dis; 2008; 17(3):129-33. PubMed ID: 18436153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease.
    Musicant SE; Taylor LM; Peters D; Schuff RA; Urankar R; Landry GJ; Moneta GL
    J Vasc Surg; 2006 Apr; 43(4):772-80; discussion 780. PubMed ID: 16616235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.